Clinical Parameter
Participants with HIV-related ocular Conditions (%) (n=27)
Participants without HIV-related ocular Conditions (%) (n=99)
CD4 count (cells/μ L)
0-50
0
2(2.0)
51-200
6(22.2)
17(17.2)
201-500
13(48.1)
56(56.6)
>500
7(25.9)
15(15.2)
Not determined
1(3.7)
9(9.1)
WHO clinical stage*
I
15(55.6)
65(65.7)
II
8(29.6)
8(8.1)
III
4(14.8)
18(18.2)
IV
0
8(8.1)
Months since HIV diagnosis
<12
2(7.4)
6(6.1)
13-24
7(25.9)
33(33.3)
25-60
16(59.3)
49(49.5)
>61
2(7.4)
11(11.1)
Months since ART started
<12
1(3.7)
12(12.1)
13-24
7(25.9)
30(30.3)
25-60
18(66.7)
51(51.5)
>61
1(3.7)
6(6.1)
Tuberculosis status
No history
13(48.1)
54(54.5)
Past history
12(44.4)
41(41.4)
Current on treatment
2(7.4)
4(4.0)
History of eye symptoms
None
4(14.8)
16(16.2)
Reduced vision
11(40.7)
53(53.5)
Pain
11(40.7)
28(28.3)
Floaters
1(3.7)
2(2.0)
*P<0.01
Table 2:
Clinical Profile of patients who are on HAART in Gondar University Hospital, Northwest Ethiopia 2010 (n=126).
